

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

DISEASE SCIENCES INC
Form 10QSB
August 16, 2002

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-QSB

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period ended JUNE 30, 2002

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____

Commission File Number: 000-27865

DISEASE SCIENCES, INC.
(Exact name of small business issuer as specified in its charter)

Delaware
(State or other jurisdiction of
Incorporation or organization)

65-1095431
(IRS Employer
Identification No.)

620 Herndon Parkway, Suite 360, Herndon, VA 20170
(Address of Principal executive offices)

Issuer's telephone number, including area code: (703) 563-6565

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15 (d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.) YES X NO_____

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 29,437,878 issued and outstanding at June 30, 2002.

DISEASE SCIENCES, INC.
TO BE RENAMED ICEWEB COMMUNICATIONS, INC.

QUARTERLY REPORT ON FORM 10-QSB FOR THE PERIOD ENDED
JUNE 30, 2002

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION
Item 1 Financial Statements

Page No.

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

Unaudited Condensed Balance Sheet at JUNE 30, 2002.....	3
Unaudited Condensed Statements of Operations for the three months and six months ended June 30, 2002 and 2001.....	4
Unaudited Condensed Statements of Cash Flows for the six months ended June 30, 2002 and 2001.....	5
Notes to Unaudited Condensed Financial Statements.....	6-14
Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations	14-22
PART II OTHER INFORMATION	
Item 6 Exhibits and Reports on Form 8-K	23
Exhibit Index	23
Signatures	23

2

Item 1. Financial Statements

DISEASE SCIENCES, INC.
TO BE RENAMED ICEWEB COMMUNICATIONS, INC.
June 30, 2002
CONDENSED BALANCE SHEET
(UNAUDITED)

ASSETS

Current assets:	
Cash	\$ 8,373
Accounts receivable	8,888

Total current assets	17,261

Property and equipment, net	175,608
Deposits	9,532
Due from related parties	73,435

Total assets	275,836
	=====
LIABILITIES AND STOCKHOLDERS' DEFICIT	
Current liabilities	
Accounts payable	\$ 219,141
Accrued expenses	53,546
Line of credit	403,015
Notes payable	257,000

Total current liabilities	932,702

Stockholders' deficit:	
Common stock, \$.001 par value; 100,000,000 shares authorized, 29,437,878 issued	29,438

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

Additional paid in capital	1,545,113
Accumulated deficit	(2,231,417)

Total stockholders' deficit	(656,866)

Total liabilities and stockholders' deficit	275,836
	=====

See notes to condensed financial statements

3

DISEASE SCIENCES, INC.
TO BE RENAMED ICEWEB COMMUNICATIONS, INC.

CONDENSED STATEMENT OF OPERATIONS
THREE AND NINE MONTHS ENDED JUNE 30, 2002 AND 2001
(UNAUDITED)

	Three Months Ended		Nine Months Ended	
	June 30		June 30	
	2002	2001	2002	2001
	-----	-----	-----	-----
Revenues	\$ 30,494	\$ 54,810	\$ 171,665	\$ 55,299
Cost of Sales	14,313	47,612	63,611	55,715
	-----	-----	-----	-----
Gross Profit	16,180	7,198	108,054	(416)
	-----	-----	-----	-----
Operating expenses:				
Marketing & sales	72,283	26,273	188,134	63,118
Research & development	26,392	10,987	69,433	10,987
General & Administrative ...	111,109	147,577	298,171	316,149
	-----	-----	-----	-----
Operating loss	(193,603)	(177,638)	(447,685)	(390,669)
	-----	-----	-----	-----
Interest (income) expense, net	88	2,662	3,527	10,184
Loss on disposal of assets	0	0	2,117	0
Depreciation and amortization	24,640	31,635	74,052	73,491
	-----	-----	-----	-----
Net loss	\$ (218,330)	\$ (211,935)	\$ (527,382)	\$ (474,344)
	=====	=====	=====	=====
Basic loss per common share	\$ (.01)	\$ (.01)	\$ (.02)	\$ (.02)
	=====	=====	=====	=====
Weighted average common shares outstanding	29,437,878	25,000,000	25,307,864	26,588,024
	=====	=====	=====	=====

See notes to condensed financial statements

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

4

DISEASE SCIENCES, INC.
TO BE RENAMED ICEWEB COMMUNICATIONS, INC.

CONDENSED STATEMENT OF CASH FLOWS
NINE MONTHS ENDED JUNE 30, 2002 AND 2001
(UNAUDITED)

	2002	2001
	-----	-----
NET LOSS	\$ (527,382)	\$ (474,344)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation & amortization	74,052	69,850
Loss on disposal of assets	4,910	-
Non-cash adjustments	(2,020)	-
Changes in assets and liabilities:		
Increase in assets	80,091	114,255
Increase in liabilities	73,059	36,868
	-----	-----
NET CASH PROVIDED (USED) IN OPERATIONS	(297,290)	(327,107)
	-----	-----
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of fixed assets	(9,695)	(228,524)
Proceeds from sale of fixed assets	10,000	-
	-----	-----
NET CASH PROVIDED (USED) BY INVESTING ACTIVITIES .	305	(228,524)
	-----	-----
CASH FLOWS FROM FINANCING ACTIVITIES		
Notes payable	257,000	11,639
Proceeds from related party	34,014	(25,697)
Contributed capital	(1,139)	-
Proceeds from private offering	-	539,500
	-----	-----
NET CASH PROVIDED (USED) BY FINANCING ACTIVITIES .	289,875	525,442
	-----	-----
NET INCREASE (DECREASE) IN CASH	(7,110)	(30,189)
CASH, beginning of period	15,484	40,192
	-----	-----
CASH, end of period	8,373	10,002
	=====	=====

See notes to condensed financial statements

5

Disease Science, Inc.
To be renamed Icweb Communications, Inc.

Notes to Condensed Financials Statements unaudited

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Financial Statements

The unaudited condensed consolidated financial statements have been prepared in

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

conformity with generally accepted accounting principles and include all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are, in the opinion of management, of a normal recurring nature. The accounting entries to record the merger with DSSC are included in the financial statements for the second quarter of fiscal year 2002 (January 2002 through March 2002). Additional information on the finances of Disease Sciences, Inc. and the merger can be found in the Form 10-KSB filed May 16, 2002; the Form 8-K filed April 4, 2002 and the Form 8-K/A filed June 16, 2002.

The results of operations for the three months and nine months ended are not necessarily indicative of those for the full year. In the opinion of management, the accompanying unaudited financial statements contain all adjustments necessary to fairly present the financial position and the results of operations for the periods indicated.

Certain information and footnote disclosures normally included in condensed consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. It is suggested that these condensed consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Company's quarterly report on Form 10-QSB for the quarter ended March 31, 2002. As stated above, the Form 8-K and Form 8-K/A that contained information on the merger between Disease Sciences, Inc. and Iceweb, Inc. should also be read.

On June 18, 2002, the Company filed a Form 8-K to change its fiscal year to October 1 through September 30. The change took effect immediately so that the current fiscal year is October 1, 2001 through September 30, 2002.

Organization

Disease Sciences, Inc., is a Delaware corporation which anticipates changing its name to Iceweb Communications, Inc. in the near future.

On March 21, 2002, Disease Sciences, Inc. executed an Agreement and Plan of Merger (DSSC Agreement) with Iceweb Communications, Inc., a Delaware Corporation and its shareholders. Under the terms of the DSSC Agreement Iceweb was acquired by and became a wholly owned subsidiary of DSSC. Pursuant to the DSSC Agreement, each of the 22,720,500 share of common stock of ICEWEB issued and outstanding immediately prior to the Merger were converted into the right to receive 1.07 shares of restricted common stock of DSSC, for an aggregate of 24,311,000 DSSC

6

Common Shares. The source of the approximately 24,311,000 DSSC Common Shares being exchanged for approximately 22,720,500 Iceweb Common Shares is as follows: 5,600,000 DSSC Common Shares were returned to the DSSC Treasury following the redemption of DSSC Common Shares; and approximately 18,711,000 additional DSSC Common Shares were issued from the DSSC Treasury. DSSC redeemed 5,600,000 Common Shares from Dr. Goldstein and Brian Johns in consideration for (a) forgiveness of \$10,000 promissory notes owing by each to DSSC; and (b) payment of \$55,000 by DSSC to each of Goldstein and John.

Each of the 5,441,000 warrants to purchase ICEWEB Common Shares issued and outstanding immediately prior to the Merger but not exercised were converted into the right to receive one warrant to purchase 1.07 Common Shares upon exercise of said warrant.

The 6,980,000 warrants to purchase DSSC Common Shares remain issued and outstanding. None of said warrants has been exercised.

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

Options to purchase ICEWEB Common Shares issued and outstanding immediately prior to the Merger but not exercised shall be converted into the right to receive one option to purchase 1.07 Common Shares upon exercise of said options.

Giving effect to the recapitalization, the exchanging Iceweb Shareholders will be the DSSC Controlling Shareholder after the Merger. DSSC will have a total of 29,460,935 shares of Common Stock issued and outstanding. The significant shareholders with 5% or more of the shares are John R. Signorello with 61.7% of the shares and Michael VanPatten with 5.12% of the shares. The closing of the agreement has resulted in a change in control of Disease Sciences, Inc.

Concurrent with the closing of the DSSC Agreement, the pre-merger Directors and Officers of DSSC were replaced by the Directors and Officers of Iceweb.

Cash Equivalents

The Company considers all highly-liquid debt instruments with original maturities of three months or less to be cash equivalents.

Property and Equipment

Property and equipment is recorded at cost and is depreciated using the straight-line method over their estimated useful lives.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

Revenue Recognition

Generally, revenues from sales of products are recognized when products are shipped unless the Company has obligations remaining under sales or

7

licensing agreements, in which case revenue is either deferred until all obligations are satisfied or recognized ratably over the term of the contract. The company uses the Percentage of Completion method to recognize revenue and expense from contracts extending through fiscal quarters.

Intangible Assets

Trademarks were acquired in September 2000. They were recorded at cost and are amortized using the straight-line method over 5 years. The Company continually reviews its intangible assets to evaluate whether events or changes have occurred that would suggest an impairment of carrying value. An impairment would be recognized when expected future operating cash flows are lower than the carrying value.

Advertising Costs

Advertising costs are included in selling expenses, and are expensed as incurred.

Amortization of Goodwill

Goodwill represents the amount by which the purchase price of a business acquired exceeds the fair market value of the net assets acquired under the

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

purchase method of accounting. The Company assesses whether its goodwill and other intangible assets are impaired as required by SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets to be Disposed of," based on an evaluation of undiscounted projected cash flows through the remaining amortization period. If an impairment exists, the amount of such impairment is calculated based on the estimated fair value of the asset. The Company determined the goodwill associated with the acquisition of American Computer Systems was impaired and the entire amount of goodwill, \$257,081 and accumulated amortization, \$102,832 was written off in September 2001.

Recent Accounting Pronouncements

On June 29, 2001, the Financial Accounting Standards Board unanimously approved the issuance of Statements of Financial Accounting Standards No. 141, Business Combinations (Statement 141), and No. 142, Goodwill and Other Intangible Assets (Statements 142). Statement 141 eliminates the pooling-of interests method of accounting for business combinations except for qualifying business combinations that were initiated prior to July 1, 2001. Statement 141 changes the criteria to recognize intangible assets apart from goodwill. The requirements of Statement 141 are effective for any business combination accounted for by the purchase method that is completed after June 30, 2001.

Under Statement 142, goodwill and indefinite lived intangible assets are no longer amortized but are reviewed annually, or more frequently if impairment indicators arise, for impairment. Identifiable intangible assets will continue to be amortized over their estimated useful lives. Early adoption is permitted for companies with fiscal years beginning after March 15, 2001, provided that their first quarter financial statements have not been issued. The Company plans to adopt Statement 142 beginning January 1, 2002. The adoption of Statement 142 is not expected to have a material impact on the Company's earnings or financial position, since Goodwill was written down to \$0 as of September 30, 2001.

8

NOTE 3 - PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

	2002	2001
	-----	-----
Furniture and fixtures	\$ 21,593	\$ 21,593
Computers and equipment	177,962	166,740
Software	96,615	0
Automobiles	3,600	17,737
Intangibles	9,676	110,587
Leasehold improvements	3,000	13,925
Accumulated depreciation	(136,838)	(45,741)
	-----	-----
Property and equipment, net	175,608	284,841
	=====	=====

NOTE 4 - OPERATING LEASES

The Company leased facilities in Chantilly, VA for office space and developmental work through May 2001 at a cost of \$2,250 per month. From June to September 2001 the Company occupied the Learning Stream office space at Silver Spring, MD; the rental expense was paid by Learning Stream, Inc. From September 15, 2001 through April 30, 2002 the Company had a sublease on space in Herndon, VA at a cost of \$5,000 per month. The Company has extended its lease at its current location for 24 months starting May 1, 2002 at an average cost of \$6,933 per month.

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

NOTE 5 - ACCOUNTS RECEIVABLE

Accounts receivable consist of normal trade receivables. The Company assesses the collectibility of its accounts receivable regularly. Based on this assessment, the Company wrote off approximately \$8,711 in delinquent accounts receivable and adjusted the allowance against accounts receivable to \$500.

NOTE 6 - RELATED PARTIES

For the period ended June 30, 2002, the company held Notes Receivable from a corporation related through common ownership and separately from a shareholder of the Company. At June 30, 2002 and 2001, the Company had a note receivable from a shareholder of \$70,230 and \$137,127. This advance is non-interest bearing and due on demand. The company advanced a corporation related through common ownership \$3,204 and \$4,242 at June 30, 2002 and 2001 respectively. The advance is non-interest bearing and due on demand.

During the years ended September 30, 2001 and 2000 a shareholder of the corporation contributed capital of \$2,280 and \$886,191, respectively to help fund operations.

The Company has a note payable for \$403,015 due to a shareholder of the Company. The note is described more fully below under NOTES PAYABLE.

9

NOTE 7 - STOCK OFFERING

In July 2000, the Company commenced a stock offering under Regulation D. The offering consisted of 10,000 units at \$100 per unit, each unit contained 500 shares of common stock at a price of \$0.20 per share. As of September 30, 2000, no common stock had been issued, nor had any funds been received. As of September 2001, approximately \$539,500 was received and approximately 2,720,500 shares of common stock had been issued. Each share of common stock that was sold was subsequently issued two warrants for each common share for a total of 5,441,000 warrants.

NOTE 8 - ACQUISITION

In June 2001, the Company executed an asset purchase agreement to purchase all the assets of Learning Stream, Inc. which is in the same line of business as the Company. The purchase price was \$173,000, which approximates the fair value of \$72,000 of computer software and \$101,000 of computer equipment acquired. The acquisition was accounted for using the purchase method of accounting. The results of operations are included in the financial statements from the date of acquisition.

NOTE 9 - SHORT-TERM DEBT

The Company had a line of credit with Merrill Lynch Business Financial Services, Inc. of up to \$500,000. The interest rate charged was based on 30-day commercial paper plus 2.4%. The interest rate was 5.07% and 8.96% as of September 30, 2001 and 2000 respectively. The line of credit was secured by the assets of the Company, and is personally guaranteed by the majority shareholder. The line of credit expired in January 2002 and was converted to a note payable to the majority shareholder.

On May 23, 2001 Disease Sciences borrowed a total of \$140,000 from two unaffiliated third parties. The notes are unsecured, payable upon demand and bear interest at 9% per year. In March 2002, payments totaling \$50,000 reduced the balance due to \$90,000. The Company is no longer accruing interest on these

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

notes and will convert them to equity.

In March 2002, a shareholder made a double payment of \$7,000 to the Company for the ongoing private placement. The amount due the shareholder has been recorded as a note payable.

In April 2002, the Company borrowed a total of \$150,000 from an unaffiliated third party. The note is unsecured and bears interest at 12.5% per year for the first seven months and 18% thereafter.

In April 2002, the Company borrowed a total of \$10,000 from an unaffiliated third party. The note is unsecured and payable upon demand. The Company will convert this note to equity.

NOTE 10 - PRIVATE PLACEMENT

Disease Sciences, Inc. completed a private placement of 4,700,000 Units (the "Units") in August of 2001. Each Unit consisted of one share of

10

common stock and four common stock purchase warrants designated Series A, Series B, Series C and Series D common stock purchase warrants (collectively the "Warrants"). The Series A Warrant included in each Unit entitles the holder to purchase one share of common stock of the Company at a purchase price of \$.30 per share. The Series B Warrant included in each Unit entitles the holder to purchase one share of common stock of the Company at a purchase price of \$.60 per share. The Series C Warrant included in each Unit entitles the holder to purchase one share of common stock of the Company at a purchase price of \$1.00 per share. The Series D Warrant included in each Unit entitles the holder to purchase one share of common stock of the Company at the purchase price of \$2.00 per share. The Warrants will expire on May 1, 2006. The Company may call any Warrant series or all of the Warrants at a call price of \$.001 per underlying share should the Company's common stock trade at or above \$5.00 per share, based on the reported closing bid price of the common stock, for 10 consecutive trading days following 15 days prior written notice of the Company's intention to call the Warrants. In the event the Warrants or Warrant series subject to call have not been exercised by written notice within such 15-day notice period, the Warrants will cease to exist.

Disease Sciences, Inc. completed a second private placement of 1,822,500 units as of March 31, 2002. Each Unit consists of one share of common stock and three common stock purchase warrants designated Series E, Series F and Series G Common Stock Purchase Warrants (collectively, the "Warrants"). Each Series E Warrant entitles the holder to purchase one share of common stock at a purchase price of \$.75 per share. Each Series F Warrant entitles the holder to purchase one share of common stock at a purchase price of \$1.50 per share. Each Series G Warrant entitles the holder to purchase one share of common stock at a purchase price of \$3.00 per share. The Warrants are immediately exercisable and will expire on October 1, 2005. Upon 15 days written notice, the Company may call any Warrant series or all of the Warrants at a call price of \$.001 per underlying share should the common stock trade at or above \$5.00 per share for 10 consecutive trading days prior to the date of such notice. The Company had sold 1,822,500 units as of March 21, 2002. The Company received a double payment from one investor for \$7,000 in March 2002; the amount has been recorded as a Note Payable to the investor for \$7,000.

NOTE 11 - Stock Options

During March 2002, the Company adopted the "Management and Director Equity Incentive and Compensation Plan." The maximum number of shares authorized and

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

available under the plan is 10,000,000 shares. As of June 30, 2002, 3,175,000 of the shares authorized under the plan have been issued. Under the terms of the plan, the options expire after 5 years, as long as the employees remain employed with the Company. The following is a summary of option activity for the nine months ended June 30, 2002.

11

	Options Available For Grant	Options Outstanding	Weighted Average Exercise Price
	-----	-----	-----
Beginning balance	10,000,000	-	-
Granted DSSC	-	2,000,000	
Granted ICEW	-	3,175,000	.20
Exercised DSSC	-	(2,000,000)	-
Cancelled	-	-	-
Balance, June 30, 2002	4,825,000	3,175,000	.20

The employee option grants provide that the option will be canceled ninety days after an employee leaves employment with the Company.

SFAS No. 123 "Accounting for Stock Based Compensation" ("SFAS 123"), requires the Company to disclose pro forma information regarding option grants made to its employees. SFAS 123 specifies certain valuation techniques that produce estimated compensation charges that are included in the pro forma results below. These amounts have not been reflected in the Company's Statement of Operations, because Accounting Principles Board Opinion 25, "Accounting for Stock Issued to Employees," specifies that no compensation charge arises when the price of the employees' stock options equal the market value of the underlying stock at the grant date, as in the case of options granted to the Company's employees

SFAS No. 123 pro forma numbers are as follows for the nine-month periods ended June 30, 2002 and 2001:

	2002	2001
	-----	-----
Actual net (loss)	(527,382)	(474,344)
SFAS 123 Compensation Cost	66,636	0
	-----	-----
Pro forma net income (loss)	(594,018)	(474,344)
	=====	=====
Pro forma basic and diluted net income (loss) per share	(.02)	(.02)
	=====	=====

Under SFAS 123, the fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The following weighted average assumptions were used:

Risk free interest rate	6%
Expected dividends	0
Volatility factor	255%
Weighted average expected life of options	5

The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. Because the Company's employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

opinion the existing models do not necessarily provide a reliable single measure of the fair value of the Company's options.

12

NOTE 12 - EARNINGS PER COMMON SHARE

Earnings per common share are calculated under the provisions of SFAS No. 128, "Earnings per Share," which established new standards for computing and presenting earnings per share. SFAS No. 128 requires the Company to report both basic earnings per share, which is based on the weighted-average number of common shares outstanding, and diluted earnings per share, which is based on the weighted-average number of common shares outstanding plus all potential dilutive common shares outstanding.

The weighted average common shares used in the computations of basic earnings per common share and earnings per common share assuming dilution are as follows:

	Three months Ended June 30		Nine months Ended June 30	
	2002	2001	2002	2001
Average common shares outstanding	29,437,878	25,000,000	25,307,864	26,588,024
Common shares issuable (1)	321,333	0	322,295	0
<hr style="border-top: 1px dashed black;"/>				
Average common shares outstanding assuming dilution (2)	29,759,211	25,000,000	25,630,159	25,871,762
<hr style="border-top: 1px dashed black;"/>				

(1) issuable under stock option plans

(2) excluded from the computation of diluted net loss per share for the periods ended June 30, 2002 because their effect would have been antidilutive

NOTE 13 - SIGNIFICANT CUSTOMER INFORMATION AND SEGMENT REPORTING

SFAS No. 131, Disclosure about Segments of an Enterprise and Related Information, establishes standards for the reporting by business enterprises of information about operating segments, products and services, geographic areas, and major customers. The method for determining what information to report is based on the way that management organizes the operating segments with Icwweb for making operational decisions and assessments of financial performance.

Icwweb's chief operating decision-maker is considered to be the chief executive officer (CEO). The CEO reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The financial information reviewed by the CEO is identical to the information presented in the accompanying condensed statements of operations. Therefore, Icwweb has determined that it operates in a single operating segment, specifically, web communications services. For the periods ended June 30, 2002 and 2001, all material assets and revenues of Icwweb were in the United States.

NOTE 14 - GOING CONCERN

The Company's auditors stated in their reports on the financial statements of the Company for the years ended September 30, 2001 and 2000 that the Company is dependent on outside financing and has had losses since inception that raise substantial doubt about our ability to continue as a going concern.

For the years ended September 30, 2001 and 2000, the Company incurred net annual losses of \$996,474 and \$707,689, respectively. Management believes that resources will be available from private and operating sources in 2002 to continue the marketing of the Company's products and services. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event the Company cannot continue in existence.

Management has established plans intended to increase the sales of the Company's products. Management intends to seek new capital from new equity securities offerings to provide funds needed to increase liquidity, fund growth and implement its business plan; however, no assurance can be given that the Company will be able to raise any additional capital.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS

The following discussion should be read together with the information contained in the financial statements and related notes included elsewhere in this report.

We Have Been The Subject Of A Going Concern Opinion From Our Independent Auditors

Our independent auditors have added explanatory paragraphs to their audit opinions issued in connection with the 2001 and 2000 financial statements which states that our Company is dependent on outside financing and has had losses since inception that raise substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Critical Accounting Policies

Financial Reporting Release No. 60, which was recently released by the U.S. Securities and Exchange Commission, encourages all companies to include a discussion of critical accounting policies or methods used in the preparation of financial statements. Our consolidated financial statements include a summary of the significant accounting policies and methods used in the preparation of our consolidated financial statements.

Management believes the following critical accounting policies affect the significant judgments and estimates used in the preparation of the financial statements.

Revenue Recognition - revenues are recognized at the time of shipment of the respective products and/or services. Our Company includes shipping and handling fees billed to customers as revenues. Costs of sales include outbound freight.

Use of Estimates

Management's discussion and analysis of financial condition and results of operations is based upon our consolidated financial statements,

which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates these estimates, including those related to allowances for doubtful accounts receivable and the carrying value of inventories and long-lived assets. Management bases these estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Plan of operation

From 1999 until June 2001, Iceweb operated as a technology hardware and software distributor business. In June 2001, we acquired the assets of Learning Stream, Inc. (LSI) in bankruptcy and changed the business model to enable interactive communication and education on the internet. Our goal is to expand our product and services offering to take advantage of what we believe to be a rapidly growing market.

Iceweb's proprietary software, IceSHOW(TM) under development since 1999 and completed in the 1st quarter 2002, allows us to create Web-ready multimedia productions very quickly, giving us a tangible competitive advantage in both time and cost. Our technology integrates audio, video and PowerPoint slides into a highly interactive, customizable interface.

Additional features can easily be added including closed captioning, indexing, animation, quizzes and surveys and pay-per-view capabilities. The software ties to a database backend that provides authentication and reporting.

Our custom services business is another service we offer our customers. Combining our technology with our experience in producing, packaging and delivering online presentations allows us to create solutions that meet specific market demands from e-learning, HR and executive communications and sales and marketing professionals.

Markets for Products and Services

Iceweb currently has customers in the training, corporate communications and advertising/marketing segments. We will focus on e-learning solutions while continuing to support the other segments as opportunities are presented.

Training - A model customer has a widely dispersed audience with regular training needs; these needs could include compliance with government regulations, skills updating or educational enhancement. For maximum benefit, the end user must have a compelling need for the training, such as license renewal, job progression or degree advancement.

15

A typical online course would include video or audio with synchronized slides, plus interactive elements such as registration, quizzes and materials downloads as well as a database to track progress, compliance and effectiveness. In addition, training companies, universities or trade associations could charge students for the course work, creating a new source of ongoing revenue. Iceweb is providing e-learning solutions for the hotel brands within the Cendant Corporation training reservations clerks worldwide.

Corporate Communications - A model customer is a corporation with offices throughout the US or the world. Iceweb's solutions could provide on-demand or

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

live streaming of executive addresses or earnings calls. They could also be used by the Human Resources department to provide orientation, introduce new benefits programs or deliver presentations to employees on compliance matters, such as sexual harassment training. This can help companies make better use of already strained budgets, as employees no longer have to take time to attend small or large group meetings and HR professionals can avoid week-long blocks of travel. Iceweb has contracts with Cendant companies to provide these services for their real estate brands.

Advertising & Marketing - Online presentations can be used to sell or market nearly any industrial or consumer product. As with any direct marketing technique, the content is of prime importance. However, studies have shown that by making the message entertaining, combining audio, video and synchronized slides, retention dramatically increases.

Iceweb has the ability to profitably sell its products and services while innovating to comply with the leading technology standards. In addition, Iceweb's education focus will allow it to market its products and services to the most rapidly growing viewing audience.

Technology

The majority of Iceweb's applications are based on client-server technology. The authoring and content management application software has been developed using a combination of ColdFusion, Javascript, ASP, VBscript, Java, and Flash. Since a majority of the processing is done on our server network, the author only needs a browser to produce and manage presentations. This keeps the need for desktop processing power to a minimum and allows for future development of enterprise solutions that can be hosted within a customer's network.

Iceweb is in the process of ensuring its course software code is compliant with AICC and SCORM computer-based training standards, so that we may integrate its solutions with those of leading Learning Management System (LMS) providers. Iceweb's software is designed for Microsoft's Windows operating systems and applications that use Microsoft's SQL 7 database software.

All Iceweb's software utilizes its original technology in one form or another. By leveraging the code of existing products, Iceweb decreases new product development costs, shortens time to market and is therefore able to realize new revenues from new products quickly.

IceSHOW(TM) is the company's core technology, a multimedia creation and delivery platform. IceSHOW's powerful feature set and intuitive viewer

16

interface are designed for ease of use. It offers great flexibility and convenience to non-technical users. Anyone with encoded media and PowerPoint slides can publish a multimedia presentation over the Internet very quickly. IceSHOW(TM) further reduces costs through an online production center. A "wizard" steps users through the process of uploading and converting existing media components, then stitching them together seamlessly. There are options for adding a branded interface and other interactive elements as well. Taking only minutes to complete (depending on the presentation length), the resulting show is ready for distribution via the Internet or an intranet.

IceSLIDE(TM) is our PowerPoint-to-Flash format conversion tool. It makes PowerPoint shows small enough to distribute via the Web or through e-mail. IceSLIDE(TM) was developed from the slide conversion technology built into IceSHOW(TM). However, IceSLIDE(TM) is a standalone application that runs on the viewer's PC. The files it creates can be uploaded into a IceSHOW(TM)

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

presentation. We currently sell IceSLIDE(TM) directly to graphics professional via our Web site.

Services

Consulting - Iceweb's consulting staff has years of experience in providing custom multimedia solutions to all size organizations. Iceweb consulting services include personalized project management, multimedia development, synchronization of all media assets, application design and development, software integration, instructional design, graphic design, foreign language translations and delivery methods. In addition to our in-house staff, we have a roster of professionals who can be contracted to provide specific expertise as needed.

IceSTUDIO(TM) Productions - Iceweb can provide audio/video studio services that a customer would need to create new audio or video assets or to transform existing media assets for Web use. Services include audio/video production, live Webcasting, audio/video editing, audio/video encoding, audio/video transcription, and voiceovers.

o Encoding - We accept source material in virtually any format to digitize and encode into a file format that is compatible with the streaming media architecture being used. In order to produce the best results, an Iceweb encoding engineer is assigned to each project to analyze critical data and apply tailored processing to ensure optimum results for that particular clip and data rates. The end result is video and audio configured properly for transmission online at the best possible resolution, motion, clarity and system compatibility, for both dial-up and broadband users.

o Webcasting - For live productions, we can produce Webcasts from a studio or from on-location. Webcasts can include audio, video, synchronized slides and graphics; shows can appear in an interface branded with your company's look and feel. Interface options include buttons for downloading additional material, sending a message to the presenter and requesting technical help. Other available features include advance user registration, user system detection, password protection, interactive surveys, quizzes and more.

17

Sales & Marketing Strategy

The potential buyers of Iceweb's products and services are organizations in both the public and private sectors with large, dispersed audiences of customers, employees, or partners. Iceweb reaches these buyers directly with its own sales organization, through telesales and direct marketing. We are also building a highly focused sales channel to refer or resell Iceweb solutions.

Marketing

Services, by their nature, are unbounded in scope. In order to create demand and reach our market quickly, we have created several service "products"; in effect, we have put boundaries around a group of services, which makes them easier to understand and therefore easier to purchase. No new technology needs to be created for these "products." Iceweb is simply using the skills and technology we already have in-house. No additional development is needed to deliver these "products."

The first set of products is being released under the brand name "IceSHOW(TM)." These are intended to be pilot programs that whet the appetite and prove the value proposition. Recognizing that a customer may want to see a deliverable before making a long-term investment, IceSHOW(TM) programs provide quick

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

turnaround of a finished online presentation. Custom options are also available.

Each package provides for on-demand viewing and includes a customized interface, login and registration forms, some level of interactivity, and hosting services for a specified period of time. They require only minimal amount of labor by Iceweb, as most of the processes used to create the presentations are automated by our technology. The products include:

- o IceSHOW(TM) e-Learning: Aimed at the educational market, this allows customers with existing content (video, slides, etc.) to quickly produce an online training session. It includes an online quiz with real-time results.

- o IceSHOW(TM) HR: For corporate HR managers who wish to contact employees with new information, for example, details on a new benefits program. It includes a survey form to poll the viewers.

- o IceSHOW(TM) Exec: This package, designed for local organizations, puts new video of an executive address online; the video can be shot in our studio or at the executive's location. It is designed for both internal announcements (to employees) and external announcements (to shareholders, business partners, customers, or the media and analyst communities).

- o IceSHOW(TM) WebVideo: Many companies have invested in corporate video productions. This package allows them to quickly put them online. The customer submits a video tape or electronic file of the original production. We provide the encoding and hosting services as well as the customized interface.

We also are launching a Web portal to deliver our customers e-learning courses. Learningstream.com provides an outlet for customers to sell

18

their online classes. Iceweb will manage the e-commerce aspects and provide payments to the course owners, in exchange for a percentage of the revenues. We will include content that we have produced for our customers as well as existing online content, or video content that we can convert for Web use. The technology to support and manage this portal is already in use, as we are currently providing these services for Fred Pryor Seminars. From an operational standpoint, Learningstream.com is merely an expansion of this existing service.

Direct mail, email and outbound telemarketing will be used to uncover new prospects and invite them to view the Iceweb Web site and learn about our targeted solutions. The site itself is regularly refreshed to include information relevant to our target audiences.

Iceweb's marketing plan also depends on the strategic application of media relations. The goal is to not only raise the company's profile, but also establish Iceweb as an expert source in the streaming media arena. PR and analyst relations can provide invaluable credibility and can often lead to sales leads.

In addition, a judicious use of trade shows will be implemented to reach highly focused audiences in specific market niches.

Sales

Our solutions are sold directly by Iceweb consultative sales personnel. Sales personnel are assigned target accounts within target markets. Some specific target markets are:

- o Repeat LearningStream, Inc. customers

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

o Training and Marketing Departments of mid- to large-size companies and trade associations in the DC metropolitan area and select companies in nearby states
o Audio & Video Production (A/V), Advertising, Promotional and Trade Show services companies who already create and produce content and wish to deliver it via the Web
o Educational institutions (schools, colleges, universities) that wish to deliver internal courseware or generate additional revenue through "e-campus" solutions.

Icweb products and services are priced competitively based on complexity and the degree of customization. We have created a number of "pilot" programs with a strict set of features in order to give prospects a quick deliverable and easy entry into online multimedia productions. These can be to whet the appetite of potentially large clients or to close prospects that wish to test the solution's capabilities in a limited fashion.

Competitive Advantages

Two major Icweb competitive advantages are its lean business model with low fixed costs and its favorable margin on products and services. Icweb's core competency of digital media production is manifested in its IceSHOW(TM) technology. It was designed to make our products and services easy and affordable, the two factors that are key for the Company to fulfill its growth expectations.

19

Our technology makes the creation of online multimedia shows easy and affordable whether Icweb is doing the work or the customers are using one of Icweb's products to do the work themselves. In either case, the cost and complexity of the development is reduced substantially. And, because Icweb's products are easy to understand and use, there is the potential for future distribution by a sales channel or network of affiliates.

Financial

Since June 2001, working capital to fund our operations was generated from the proceeds of \$539,500 received by us from the private placement of our securities and also from sales of our product and services to both legacy LSI customers and new customers.

Net revenues - for the nine months and three months ended June 30, 2002, we generated revenues of \$171,665 and \$30,494 respectively compared to \$55,299 and \$54,810 in each of the comparative periods in 2001. Sales for the three months ending June 30, 2002 were lower than the previous quarter and lower than the same quarter for the previous fiscal year. The primary reason for this was a change in our marketing and sales strategy to build our business around the IceShow products. Sales from both custom services and webcasts were lower this quarter than in the previous quarter due in part to hiring and training new salespersons. We also changed our E-commerce business to sell third-party classes and on-line training over the internet.

Cost of revenues - our cost of revenues consists of costs related to production of custom services, internet and telephony communication access costs, personnel, and technical support. Our cost of revenues as a percentage of total revenues decreased for both the nine months and three months ending June 30, 2002 over the respective periods in 2001 by 37% and 40%. This was primarily due to conversion of our production costs to a variable from a fixed expense, better bidding on new projects and more aggressive control of costs.

Marketing and Sales - our sales and marketing expense consists of personnel costs, including commissions, public relations, advertising, marketing

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

programs, lead generation, travel and trade shows. Marketing and sales costs increased for the nine and three months ending June 30, 2002 over the same periods in 2001 by \$125,016 and \$46,010 respectively. This increase was the result of continued upgrading of our sales and marketing personnel, commission expenses and marketing programs.

Research and development - our research and development expense consists mostly of salaries, personnel related expenses, supplies, equipment and engineering services. Expenses increased by \$58,446 and \$15,405 for the nine and three month period ending June 30, 2002 from the respective periods in 2001. This increase is our investment in the development of the IceSHOW software. We plan on using this software as the foundation for our product offerings in the future.

General and administrative expense - our general and administrative expense consists primarily of personnel costs, rent, legal, accounting, human resources, telecommunications, office supplies and corporate governance and compliance. General and administrative expense

20

decreased for the nine and three months ending June 30, 2002 over the same periods in 2001 by \$17,978 and \$36,468 respectively. The primary reasons for this were a reduction in rent expense and the fact that the LSI acquisition costs occurred in June 2001. This also represents our success in operational efficiency initiatives to streamline work processes to permanently reduce the Company's overall cost structure.

Income taxes - because we incurred net operating losses in the three and nine months ended June 30, 2002, we paid no federal, state or foreign income taxes in those periods. We have also not recognized any tax benefits for the related tax operating loss carryforwards and may not until we conclude that such benefits will be utilized.

Overall, our loss per share was \$(.02) for the nine months ended June 30, 2002 and 2001 and \$(.01) for the three months ending June 30, 2002 and 2001. The lower loss per share in the third quarter of 2002 is due primarily to the increase in the number of shares of stock associated with the Disease Sciences merger. For the third quarter 2001, the reason was the stock issued included the Evolve One shares that were returned in September 2001. For the balance of this fiscal year we anticipate that our loss per share may increase.

We expect to generate losses resulting principally from costs incurred in conjunction with our marketing and sales and research and development initiatives, and we expect that the costs of these activities will increase as the implementation of our business plan continues. However, as we continue to implement our plan of operation, we expect general and administrative expenses to remain nearly flat and actually decrease as a percentage of sales due to the process efficiencies we have already put in place.

In order to provide sufficient working capital to fund our ongoing operations we will be required to raise additional capital to fund these anticipated costs. There are no assurances that we will be able to obtain the additional capital in which event our future operations would be materially and adversely affected.

Liquidity and Capital Resources

Since inception, our operating and investing activities have used more cash than they have generated. Because of the continued need for substantial amounts of working capital to fund the growth of the business, to meet our commitment for research funding and to pay our operating expenses, we expect to continue to experience significant negative operating and investing cash flows for the

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

foreseeable future. Our existing working capital will not be sufficient to fund the continued implementation of our plan of operation during the next 12 months and to meet our capital commitments and general operating expenses. We are unable to predict at this time the exact amount of additional working capital we will require, however, in order to provide any additional working capital which we may require, we will in all likelihood be required to raise additional capital through the sale of equity or debt securities. We currently have no commitments to provide us with any additional working capital. If we do not have sufficient working capital to implement our plan of operation described above, it is likely that we will cease operations.

21

Cautionary Factors That May Affect Future Results

This report and other written reports and oral statements made from time to time by the Company may contain so-called "forward-looking statements," all of which are subject to risks and uncertainties. One can identify these forward-looking statements by their use of words such as "expects," "plans," "will," "estimates," "forecasts," "projects" and other works of similar meaning. One can identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company's growth strategy, financial results, and product and development programs. One must carefully consider any such statement and should understand that many factors could cause actual results to differ from the Company's forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.

The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors described in the Company's filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In various filing the Company has identified important factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete list of all potential risks or uncertainties.

Part II - OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 2. Changes in Securities

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Submission of Matters to a Vote of Security Holders

None.

Item 5. Other Information

Edgar Filing: DISEASE SCIENCES INC - Form 10QSB

None.

22

Item 6. Exhibits and Reports on Form 8-K

Exhibit 99.1 - Certification of Quarterly Reports for the period ending June 30, 2002 by the Principal Executive Officer and the Principal Financial Officer.

During the three month period from March 31, 2002 to June 30, 2002, the Company filed or furnished:

- (a) A current report on Form 8-K filed on April 4, 2002 pertaining to the Merger between Disease Sciences and Iceweb.
- (b) A current report on Form 8-K filed on May 16, 2002 pertaining to the change in registrants certifying accountant.
- (c) A current report on Form 8-K filed on June 11, 2002 amending the Form 8-K filed on May 16, 2002.
- (d) A current report on Form 8-K filed on June 18, 2002 changing the fiscal year.
- (e) A current report on Form 8-K filed on June 18, 2002 amending the Form 8-K filed on May 16, 2002.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Disease Sciences, Inc.

By: /s/ John R. Signorello

John R. Signorello,
Chairman and CEO

Dated: August 16, 2002

23